Sepracor "outperform," target price raised

11/20/06 - Credit Suisse

NEW YORK, November 20 (newratings.com) - Analyst M Goodman of Credit Suisse maintains his "outperform" rating on Sepracor Inc (SEPR). The target price has been raised from $60 to $65.

In a research note published this morning, the analyst mentions that the transition for inhalers from CFCs to HFAs is likely to be quicker than was earlier expected on account of a pick up in the phase down of CFC production. This is likely to result in continued acceleration in Xopenex MDI Rxs, with significant growth in 2007 and 2008, the analyst says. Lunesta TRxs have continued to accelerate, since the sleep disorder market and Lunesta's market share are growing, Credit Suisse adds.